MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from venture
loan and security...
$29,337,000
Net cash provided by
financing activities
$27,523,000
Canceled cashflow
$1,814,000
Net increase in cash
and cash...
$14,203,000
Canceled cashflow
$13,320,000
Payment of venture loan
and security...
$1,814,000
Accounts payable
$3,161,000
Stock-based compensation
$1,908,000
Accretion of interest for
royalty obligations
$1,077,000
Amortization of intangible
assets
$1,031,000
Prepaid expenses
-$498,000
Depreciation of property and
equipment
$469,000
Amortization of debt discount
$195,000
Inventory
-$156,000
Operating lease
right-of-use assets
-$104,000
Lease amortization
expense
$70,000
Net cash used in
operating activities
-$13,126,000
Net cash used in
investing activities
-$194,000
Canceled cashflow
$8,669,000
Net loss
-$10,238,000
Change in fair value of
convertible notes
$5,203,000
Purchases of property and
equipment
$194,000
Accounts receivable
$2,842,000
Accrued expenses
-$1,908,000
Contingent consideration
-$1,200,000
Deferred revenue
-$241,000
Operating lease
liabilities
-$163,000
Back
Back
Cash Flow
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)
source: myfinsight.com